Neoantigen × AI
Daily research signal
№48Brief

Personalized melanoma vaccine cuts recurrence risk in phase 3

Personalized neoantigen mRNA vaccines moved from phase 2 promise to phase 3 evidence this cycle: newly released INTerpath-001 data show the vaccine-plus-pembrolizumab regimen reduced two-year recurrence or death risk in resected melanoma.Medical Xpress

That clinical signal frames Moderna's November 5 Q3 call, where late-stage results for its Merck-partnered personalized cancer vaccine intismeran autogene are a stated focal point.TradingView The investor tension is clear: oncology validation is arriving just as the category's leading sponsor faces a valuation debate and questions about which trials survive cost discipline.TradingView

2new stories
ClinicalyesterdayNew

Personalized vaccine targets melanoma recurrence - Medical Xpress

Newly released phase 3 INTerpath-001 results show a personalized mRNA vaccine combined with pembrolizumab reduced the risk of melanoma recurrence or death at two years versus pembrolizumab alone after surgery, building on the phase 2 KEYNOTE-942 evidence that first established the approach. Sutter Health investigators Dr. Kevin Kim, chief of precision medicine, and Dr. Mohammed Kashani-Sabet, medical director of Sutter CPMC's Cancer Center, led Sutter's participation in KEYNOTE-942. Each vaccine is personalized using the patient's unique tumor genomic profile, training the immune system to recognize and attack cancer cells. Why it matters: this is the individualized neoantigen mRNA modality advancing from promising phase 2 data to large international phase 3 confirmation in the adjuvant melanoma setting.

news · yesterday · Medical Xpress

01

01
CommercialyesterdayNew

Moderna to report Q3 amid valuation debate, cancer vaccine results: What to expect - TradingView

Moderna reports Q3 on November 5 after the close, with Wall Street modeling a loss of $1.35 per share on revenue of $890.22M, a 12.7% Y/Y decline; over the past three months EPS estimates saw 1 upward and 2 downward revisions while revenue estimates saw 7 upward and 5 downward moves. Analysts will watch total vaccine sales and pricing, cash outflows, retail and health-system contracts for next season, and the 2027-2028 outlook, with Seeking Alpha's Lee Bailey flagging which trials would feel the pinch if management tightens spending again. The major focal point is late-stage trial results for intismeran autogene, the personalized cancer vaccine in development with Merck. Why it matters: the oncology readout lands mid-valuation-debate, making pipeline funding priorities as consequential as the quarterly miss.

news · yesterday · TradingView